Buscar
Congreso SOLACI
HomeInternational CongressesEUROPCR 2019

EUROPCR 2019

Ver Categoría
Chronic Ischemic cardiopathy

What Happens When We Are Blinded by Left Main Disease and Ignore All Other Lesions?

According to this recent Excel analysis, mortality seems to rise when the SYNTAX II score is not...
solaci -
Ver más
STRUCTURAL HEART DISEASE

Prosthetic Valve Endocarditis and TAVR: though Rare, Devastating

On the bright side, the incidence of prosthetic valve endocarditis (PVE) post TAVR is not higher than...
solaci -
Ver más
Coronary disease

EuroPCR 2019 | MeRes-1: Bioresorbable Scaffolds Return with Renewed Strength

A small number of highly selected patients presents good outcomes with new bioresorbable scaffold MeRes, but much...
solaci -
Ver más
STRUCTURAL HEART DISEASE

EuroPCR 2019 | Most Recent TAVR Meta-Analysis: The Spectrum of Treatment Reaches All Patients

This new meta-analysis combines all randomized transcatheter aortic valve replacement (TAVR) vs. surgical aortic valve replacement trials...
solaci -
Ver más
Femoropopliteal

EuroPCR 2019 | EFFPAC: New Peripheral Paclitaxel Coated Balloons, Efficacy with no Sign of Mortality

Paclitaxel coated balloons in peripheral territory have been under the spotlight for alleged increased mortality, which even...
solaci -
Ver más
STRUCTURAL HEART DISEASE

EuroPCR 2019 | Leaflex: New Device for Pre-TAVR Calcium Fracture

Researchers behind this small study believe that fracturing the rigid calcium deposits on leaflets with this new...
solaci -
Ver más
PERIPHERAL VASCULAR DISEASE

EuroPCR 2019 | TAVR Durability Offers Certain Guarantees at 8 and 10 Years

It has been 3 years since EuroPCR 2016 and the presentation of the first data on possible...
solaci -
Ver más
STRUCTURAL HEART DISEASE

EuroPCR 2019 | Long-Term Follow-Up for New Left Bundle Branch Block After TAVR Is Reassuring with Certain Precautions

Long-term follow-up of patients who underwent transcatheter aortic valve replacement (TAVR) and developed left bundle branch block...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

TCT 2024 | FAVOR III EUROPA

Dr. Carlos Fava - 0
The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

Dr. Carlos Fava - 0
This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Dr. Omar Tupayachi - 0
Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

Noticias Institucionales

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Arequipa Sessions 2024: Meet the International Guests

solaci - 0
The Arequipa Sessions 2024 is getting closer and closer. Meet the international guests who will share their knowledge for 2 days at a high-level...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad